A phase II study of hypofractionated proton therapy for prostate cancer

Acta Oncologica

Volumn 52, Issue 3, 2013, Pages 477-485

  Kim, Yeon Joo ^a   Cho, Kwan Ho ^a   Pyo, Hong Ryull ^b   Lee, Kang Hyun ^a   Moon, Sung Ho ^a   Kim, Tae Hyun ^a   Shin, Kyung Hwan ^a   Kim, Joo Young ^a   Lee, Se Byeong ^a   Nam, Byong Ho ^a  

^a National Cancer Center   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT 60; PROTON;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROTON RADIATION; PROTON THERAPY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; ACUTE TOXICITY; ANDROGEN DEPRIVATION THERAPY; DRUG DOSE REGIMEN; FEASIBILITY STUDY; GASTROINTESTINAL TOXICITY; GENITOURINARY TOXICITY; HUMAN TISSUE; HYPOFRACTIONATED PROTON THERAPY; INVESTIGATIVE PROCEDURES; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; SKIN TOXICITY; TOXICITY; UROGENITAL TRACT DISEASE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DOSE FRACTIONATION; FEASIBILITY STUDIES; GASTROINTESTINAL TRACT; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROTON THERAPY; RADIATION INJURIES; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RECTUM; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER;

EID: 84875201524     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.764011     Document Type: Article

References (22)

1. Hausterman K, Fowler JF. A comment on proliferation rates in human prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:303 (Pubitemid 30488242)
2. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-101 (Pubitemid 29144800)
3. Fowler J. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003; 56:1093-104 (Pubitemid 36794043)
4. Fowler J, King CR. Don't squeeze hypofractionated schedules into too-short overall times. Int J Radiat Oncol Biol Phys 2009;75:323-5
5. Slater JD, Rossi CJ, Jr., Yonemoto LT, Bush DA, Jabola BR, Levy RP, et al. Proton therapy for prostate cancer: The initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 2004;59:348-52 (Pubitemid 38622585)
6. Perez CA, Michalski J, Mansur D, Lockett MA . Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate. Cancer J 2004;10:349-56 (Pubitemid 44313542)
7. Fowler JF, Harari PM, Leborgne F, Leborgne JH. Acute radiation reactions in oral and pharyngeal mucosa: Tolerable levels in altered fractionation schedules. Radiother Oncol 2003;69:161-8 (Pubitemid 37485875)
8. Dorr W, Hamilton CS, Boyd T, Reed B, Denham JW. Radiation- induced changes in cellularity and proliferation in human oral mucosa. Int J Radiat Oncol Biol Phys 2002; 52:911-7 (Pubitemid 34219008)
9. Yoon M, Kim D, Shin DH, Park SY, Lee SB, Kim DY, et al. Inter- and intrafractional movement-induced dose reduction of prostate target volume in proton beam treatment. Int J Radiat Oncol Biol Phys 2008;71:1091-102
10. Simon R, Wittes R, Ellenberg S. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375
11. Barry MJ, Fowler FJ, Jr., O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the A merican Urological Association. J Urol 1992;148:1549-57; discussion 64
12. LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys 1995;31:1049-91
13. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 2003;41:582-92
14. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78:11-8
15. Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari MG, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011;79:1013-21
16. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007;68:1424-30 (Pubitemid 47176809)
17. Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, et al. Phase II trial of hypofractionated imageguided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 69:1084-9 (Pubitemid 47625844)
18. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys 2007;67:1099-105
19. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti Jr JC. Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009;73: 1043-8
20. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105
21. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74 (Pubitemid 350251041)
22. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-61 (Pubitemid 351439226)